Last reviewed · How we verify
Ethyl chloride skin refrigerant spray
Ethyl chloride skin refrigerant spray, developed by Weill Medical College of Cornell University, is a marketed product used for topical anesthesia and pain relief. The key composition patent expires in 2028, providing a period of exclusive market protection. The primary risk is the potential for generic competition post-patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Ethyl chloride skin refrigerant spray |
|---|---|
| Sponsor | Weill Medical College of Cornell University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety of Gebauer's Pain Ease and Gebauer's Ethyl Chloride (PHASE4)
- The Evaluation of External Thermomechanical Stimulation for Pain Reduction in Patients Undergoing Nail Injection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: